The urgency behind the work is difficult to overstate. Staphylococcus aureus sits at the center of the global antimicrobial resistance crisis, a problem whose scale has been quantified with growing alarm. A 2024 systematic analysis in The Lancet projected that bacterial antimicrobial resistance could be associated with tens of millions of deaths annually by mid-century if current trends continue. Part of what makes S. aureus so difficult to eradicate is its ability to form biofilms—structured communities of cells encased in a self-produced matrix of extracellular polymeric substances. Within these slimy fortresses, bacteria can tolerate antibiotic concentrations hundreds to thousands of times higher than their free-floating planktonic counterparts would survive. Biofilms on catheters, implants, heart valves, and chronic wounds effectively shield the pathogens from both immune attack and conventional drugs, making biofilm disruption a central goal of modern anti-infective research.

Desmodium gangeticum, a member of the legume family Fabaceae, has been used for centuries across the Indian subcontinent and Southeast Asia in formulations for fever, inflammation, wounds, and digestive ailments. Previous pharmacological investigations have attributed anti-inflammatory, antioxidant, antileishmanial, cardioprotective, and even anticancer properties to its roots and aerial parts, and earlier work had hinted at quorum-quenching activity in related contexts. What remained unclear was precisely which chemical constituents drive antibacterial activity against S. aureus, whether extraction solvent influences that activity, and whether the plant’s chemistry can physically disable the machinery the bacterium uses to adhere, colonize, and regulate virulence. The new study set out to answer these questions systematically.

The research team prepared three different leaf extracts using solvents of increasing polarity—acetone, ethyl acetate, and methanol—and subjected each to a battery of phytochemical and biological assays. Solvent choice matters enormously in natural product chemistry because different classes of secondary metabolites dissolve preferentially in different media: polar methanol tends to pull out phenolics and flavonoids, while intermediate-polarity ethyl acetate often extracts terpenoids and sterols. Gas chromatography–mass spectrometry (GC-MS) profiling of the extracts revealed a rich pharmacological repertoire, including the triterpene lupeol, the isoprenoid squalene, Vitamin E (alpha-tocopherol), the phytosterol stigmasterol, palmitic acid, the indole-containing compound 1-(6-fluoro-1H-indol-3-yl)propan-2-amine, and alpha-tocospiro B. Several of these molecules already carry documented antimicrobial or anti-inflammatory credentials, giving the extracts a plausible mechanistic foundation.

On the antioxidant front, the methanolic extract proved the clear champion. In the DPPH (2,2-diphenyl-1-picrylhydrazyl) radical-scavenging assay, a standard colorimetric test in which antioxidant capacity is expressed as the concentration needed to quench half of the stable free radicals, the methanolic extract achieved an IC50 of 84.37 ± 4.5 micrograms per milliliter. In the phosphomolybdenum total antioxidant capacity assay, it delivered 159.1 ± 13.68 micrograms of ascorbic acid equivalents per milligram of dried extract—a substantial figure indicating that a single milligram of the dried extract carries antioxidant reducing power equivalent to roughly 159 micrograms of vitamin C. These results align with the high total phenolic and flavonoid content typically recovered in methanolic extracts and suggest the plant could also be valuable as a source of natural antioxidant preservatives or nutraceutical ingredients.

But it is the antibacterial and antibiofilm results that carry the most immediate clinical significance. When the extracts were tested against S. aureus using broth microdilution methods to determine minimum inhibitory concentrations (MIC) and minimum bactericidal concentrations (MBC), the ethyl acetate extract outperformed its counterparts, inhibiting bacterial growth at the remarkably low concentration of 0.61 ± 0.2 milligrams per milliliter and achieving complete bacterial killing at an MBC of 3 milligrams per milliliter. An MBC within roughly fourfold of the MIC indicates genuinely bactericidal rather than merely bacteriostatic activity—a distinction that matters when designing therapies for immunocompromised patients who cannot rely on their own immune systems to finish the job.

Even more striking was the biofilm disruption data. Mature S. aureus biofilms, once established, are notoriously recalcitrant to treatment, yet the ethyl acetate extract disrupted an average of 88.95 ± 0.77 percent of established biofilm biomass in vitro. The researchers corroborated this quantitative result with scanning electron microscopy, which qualitatively revealed the structural devastation inflicted on the biofilm architecture—the dense, multilayered bacterial communities and their extracellular matrix visibly dismantled in the presence of the extract. Disrupting existing biofilms is generally considered a harder problem than preventing biofilm formation in the first place, and an activity approaching ninety percent against mature structures places this plant extract among the more promising natural anti-biofilm candidates described in recent literature.

To move from observation to mechanism, the team turned to computational structural biology. The major compounds identified by GC-MS were docked against a panel of eight S. aureus proteins that occupy central positions in the bacterium’s virulence and resistance networks: accessory gene regulator A (AgrA) and accessory gene regulator C (AgrC), which together form the quorum-sensing two-component system controlling virulence factor expression; clumping factor A and clumping factor B, surface adhesins that mediate attachment to host tissues and biomaterials; dehydrosqualene synthase, an enzyme in the staphyloxanthin pigment pathway that helps the bacterium survive oxidative attack by host immune cells; fibronectin-binding protein A, another key invasion factor; penicillin-binding protein 2, the transpeptidase targeted by beta-lactam antibiotics including methicillin; and Staphylococcus accessory regulator A (SarA), a global transcriptional regulator of exoprotein and adhesin genes. Using AutoDock Vina-based docking protocols, the analysis demonstrated high binding affinities of the plant compounds for these targets, with several ligand–protein pairs showing binding energies competitive with known inhibitors.

The in silico picture is internally consistent with the in vitro observations. AgrA, AgrC, and SarA collectively orchestrate the regulatory switch that drives biofilm maturation and toxin production, so compounds binding these regulators would be expected to weaken biofilm integrity—precisely the near-total disruption observed experimentally. Similarly, strong docking poses at clumping factors and fibronectin-binding protein A predict impaired initial surface adherence, while activity at penicillin-binding protein 2 hints at a direct hit on cell-wall synthesis, the same vulnerability exploited by frontline antibiotics that many clinical strains have learned to evade. Docking predictions of this kind are, of course, hypotheses rather than proof—binding energies computed in silico do not guarantee inhibition in living cells—and the authors are appropriately cautious, emphasizing that further pharmacological and clinical validation is required before any therapeutic claims can be made.

Even so, the convergence of evidence is compelling. This is not a study of a single crude extract showing vaguely antibacterial activity; it is a solvent-stratified phytochemical analysis paired with quantitative bactericidal testing, biofilm disruption assays, electron microscopy, and target-level computational modeling, all pointing in the same direction. The identified lead compounds—lupeol, squalene, Vitamin E, and stigmasterol—are themselves well-characterized molecules with existing safety and toxicology literature, which could accelerate any downstream development. Lupeol in particular has recently attracted attention for its ability to modulate bacterial efflux pumps and attenuate biofilm formation in other pathogens, and squalene has been reported to inhibit S. aureus virulence in food-borne contexts, findings that resonate with the docking results reported here.

The broader lesson may extend beyond one plant and one pathogen. As the pharmaceutical pipeline for antibiotics thins and multidrug-resistant S. aureus strains, including MRSA, continue to spread through hospitals and communities worldwide, medicinal plants with documented ethnopharmacological use represent an enormous, largely untapped library of bioactive chemistry. Desmodium gangeticum exemplifies the strategy: a species whose traditional credentials guided modern screening, whose chemistry yielded concrete molecular leads, and whose extracts attack the pathogen on multiple fronts—oxidative stress, cell viability, and biofilm architecture—simultaneously. The next steps will be demanding: isolation and testing of individual compounds, synergy studies, toxicity and ADME profiling, and ultimately in vivo efficacy models. But for a pathogen that has outmaneuvered nearly every antibiotic class humans have deployed, an ancient legume leaf that dismantles its fortresses nearly ninety percent is news worth taking seriously.

Alzheimer’s disease, a debilitating condition affecting millions globally, is marked by progressive cognitive decline and is currently without a definitive cure. The urgency for effective treatments has prompted the exploration of various novel compounds targeting the underlying mechanisms of the disease, including amyloid-beta deposition, tau protein aggregation, and neurotransmitter deficiencies. In this context, the design and synthesis of hybrid compounds such as thiadiazole-thiazolidinone chalcones emerge as a beacon of hope.

In their study, Khan and colleagues started with a solid theoretical foundation, employing computational tools to simulate the interactions between these chalcones and various biological targets related to Alzheimer’s pathogenesis. The computational phase involved molecular docking studies, predicting how well these compounds might bind to specific proteins implicated in the disease process. This initial step is vital, as it allows researchers to screen large numbers of potential candidates quickly and efficiently before moving on to more resource-intensive experimental validation.

The molecular design of thiadiazole-thiazolidinone hybrid chalcones was carefully crafted to optimize their drug-like properties. By integrating diverse pharmacophores known to exhibit neuroprotective benefits, the researchers aimed to enhance both the potency and selectivity of these compounds. This approach underscores a growing trend in drug discovery: the creation of hybrids that capitalize on synergistic effects often seen in polypharmacology, where one compound can simultaneously target multiple pathways, potentially yielding better therapeutic outcomes.

Once promising candidates were identified computationally, the next phase was empirical validation through synthesis and biological testing. The synthesis of these hybrid chalcones was a complex process, requiring careful control of reaction conditions to ensure high yield and purity. The researchers meticulously reported their synthetic routes and characterized the compounds using a combination of spectroscopic techniques, confirming the successful formation of the desired thiadiazole-thiazolidinone scaffolds.

Biological evaluations were crucial in determining the efficacy of these newly synthesized compounds. The in vitro assays focused on assessing the compounds’ neuroprotective effects against pathological agents associated with Alzheimer’s, including lectins and inflammatory markers. These studies are fundamental for revealing how well these hybrid chalcones can preserve neuronal function and viability in the face of various neurotoxins.

The researchers also leveraged various cell culture models to mimic the Alzheimer’s disease environment more accurately. This included utilizing neuronal cell lines that exhibit characteristics akin to early-stage Alzheimer’s pathology. By introducing amyloid-beta plaques or tau tangles into the culture system, they could observe how their compounds influenced cell survival, inflammatory responses, and neurogenesis, contributing significantly to understanding potential therapeutic mechanisms.

Furthermore, Khan et al. extended their study to include computational modeling of pharmacokinetics and toxicity. Assessing the drug-like properties and safety profiles of these chalcones is crucial for their future development as therapeutic agents. This modeling evaluates absorption, distribution, metabolism, excretion, and toxicity (ADMET) parameters, identifying candidates that are not only effective but also suitable for further clinical development.

An essential part of their approach was the collaborative nature of the research, which brought together experts in computation, synthesis, and pharmacology. This multidisciplinary strategy exemplifies modern drug discovery, where collaboration across various scientific domains results in more robust and comprehensive outcomes. By fostering a collaborative environment, the research team could address the multifaceted challenges presented in developing new Alzheimer’s therapeutics.

The findings from this research offer a solid foundation for further exploration into thiadiazole-thiazolidinone hybrid chalcones. They not only enhance our understanding of potential neuroprotective compounds but also illustrate the significance of integrating computational modeling with experimental research. This dual approach allows for a more streamlined and informed discovery process, potentially leading to breakthroughs in Alzheimer’s treatment paradigms.

As the study progresses towards in vivo evaluations, the excitement builds within the scientific community. If these chalcones display efficacy in animal models, it could pave the way for clinical trials aimed at assessing their therapeutic potential in humans. The journey from bench to bedside may soon witness a genuine contender in the fight against Alzheimer’s, driven by the remarkable innovations stemming from this research.

In summary, the work by Khan and his collaborators not only sheds light on a new class of hybrid compounds with therapeutic potential against Alzheimer’s disease but also emphasizes the importance of a multidisciplinary approach in modern medicinal chemistry. Their research provides a key stepping stone toward developing innovative strategies to tackle one of the most pressing health issues of our time, with implications that could extend far beyond Alzheimer’s disease itself.

Thus, the exploration of thiadiazole–thiazolidinone hybrid chalcones holds significant promise, highlighting how blending computational methods with traditional laboratory techniques can yield profound insights that might very well change the landscape of Alzheimer’s treatment in the years to come.

Subject of Research: Thiadiazole-thiazolidinone hybrid chalcones for anti-Alzheimer potentials.

Article Title: From concept to simulations: computational and experimental assessment of thiadiazole–thiazolidinone hybrid chalcones for anti-alzheimer potentials.

Article References:

Khan, M.B., Khan, S., Iqbal, T. et al. From concept to simulations: computational and experimental assessment of thiadiazole–thiazolidinone hybrid chalcones for anti-alzheimer potentials.
3 Biotech 16, 42 (2026). https://doi.org/10.1007/s13205-025-04648-0

Image Credits: AI Generated

DOI: https://doi.org/10.1007/s13205-025-04648-0

Keywords: Alzheimer’s disease, thiadiazole, thiazolidinone, hybrid chalcones, neuroprotection, medicinal chemistry, drug discovery.

The pivotal aspect of this study lies in the integrative gene target mapping, which allows researchers to assertively identify key genes involved in the pathogenesis of type 1 diabetes. This mapping serves as the foundation for further investigative procedures, ensuring that subsequent analyses are deeply rooted in a strong genetic framework. By pinpointing critical genetic targets, the researchers are enabling a molecular-level understanding of the disease, paving the way for tailored therapeutic strategies that may one day fundamentally alter the treatment landscape for patients suffering from this debilitating condition.

RNA sequencing represents another cornerstone of this study, offering invaluable insight into the transcriptomic landscapes of pancreatic cells affected by type 1 diabetes. This cutting-edge technology allows for the quantification and comparison of RNA transcripts, providing a clear picture of gene expression patterns. Through their RNA sequencing analysis, Vastrad and colleagues could identify which genes are upregulated or downregulated in the presence of certain marine-derived compounds. This knowledge is essential not just for understanding the biological underpinnings of the disease but also for discerning how these novel compounds might interact with the genetic framework of type 1 diabetes.

Complementing the findings from gene mapping and RNA sequencing is the innovative use of in silico molecular docking. This computational technique enables researchers to simulate the binding of marine-derived molecules with specific target proteins implicated in type 1 diabetes. It reveals not just the potential efficacy of these compounds in terms of their ability to bind effectively to their molecular targets, but also their specificity, which is crucial for minimizing side effects in real-world clinical applications. The study’s findings in this area suggest promising interactions between specific marine extracts and the molecular targets identified through integrative mapping, further corroborating the therapeutic potential of these compounds.

While the in silico molecular docking provides an initial perspective on interactions at the molecular level, the ADMET profiling takes the investigation a step further. ADMET, which stands for Absorption, Distribution, Metabolism, Excretion, and Toxicity, is critical in assessing the viability of new pharmaceutical agents. By thoroughly evaluating these parameters for the identified marine-derived molecules, the researchers are ensuring that potential treatments are not only effective but also safe for human use. The study reinforces the importance of comprehensive profiling in drug discovery, highlighting that a theoretically effective compound must also possess favorable pharmacokinetic and toxicity profiles.

The application of molecular dynamics simulations showcases the dynamic nature of molecular interactions over time. This technique provides a real-time view of how marine-derived compounds behave in a biological environment, revealing their stability and potential impacts on target proteins. The use of such simulations illustrates the sophistication of the study, as these dynamic models enable researchers to predict the efficacy of the compounds under physiological conditions. Such advanced modeling techniques contribute immensely to the development of more reliable and effective treatments for type 1 diabetes.

Furthermore, the implications of this multifaceted research extend beyond the immediate findings. By exploring the potential of marine-derived molecules, the study opens up new avenues for drug discovery and development. It encourages further investigation into the untapped pharmacological properties of marine organisms, which have historically been overlooked in favor of terrestrial sources. As researchers delve deeper into the chemical diversity found in marine life, the potential for novel therapeutic agents continues to grow, enriching the pharmacological arsenal available for tackling chronic diseases such as diabetes.

The implications of these findings also resonate within the broader context of precision medicine. As our understanding of individual genetic factors in diseases like type 1 diabetes increases, the potential for personalized therapy becomes more feasible. This study not only elucidates specific targets for treatment but also points towards a future where therapies can be tailored to individual genetic profiles, maximizing effectiveness while minimizing adverse effects. The confluence of marine biotechnology with personalized medicine could redefine how diabetes is managed, making it a vital area of research moving forward.

As researchers like Vastrad and his team continue to explore the intersection of marine biology and medicine, the rising tide of innovation promises exciting prospects for patients and healthcare providers. There remains much work to do in validating the therapeutic efficacy of these marine-derived compounds through clinical trials and other rigorous evaluations. However, the groundwork laid by this study is undoubtedly promising; it not only highlights the innate potential of unexplored marine resources but also inspires a renewed commitment to interdisciplinarity in research.

As the study progresses to the next stages of research, collaborative efforts across various scientific domains will be crucial. Engaging molecular biologists, pharmacologists, and clinical researchers is essential for translating these initial findings into clinically viable treatments. The message is clear: significant breakthroughs often arise from the integration of diverse scientific perspectives and methodologies, and this study serves as an exemplary model.

In conclusion, the research spearheaded by Vastrad, Pattanashetti, and Sadashivanavar represents a significant step forward in the quest to understand type 1 diabetes through the lens of marine-derived molecules. The combination of meticulous gene mapping, sophisticated RNA sequencing, advanced molecular docking techniques, and thorough ADMET profiling together contributes to a richer understanding of the potential therapeutic avenues that lie in the depths of our oceans. As the scientific community eagerly anticipates the next stages of investigation, the initial findings already weave a compelling narrative of hope and innovation—a potent reminder of the remarkable possibilities that exist when nature and science converge in the fight against chronic diseases like diabetes.

The journey of exploration is just beginning, and it is likely that the discoveries derived from this research will inspire further investigations into the pharmacological potential of marine biological resources. Indeed, as this study illustrates, the ocean’s bounty may hold the key to the future of diabetes treatment, illuminating a pathway toward more effective and personalized healthcare solutions.

Subject of Research: Marine-derived molecules for type 1 diabetes mellitus

Article Title: Integrative gene target mapping, RNA sequencing, in silico molecular docking, ADMET profiling and molecular dynamics simulation study of marine derived molecules for type 1 diabetes mellitus.

Article References:
Vastrad, B., Pattanashetti, S., Sadashivanavar, V. et al. Integrative gene target mapping, RNA sequencing, in silico molecular docking, ADMET profiling and molecular dynamics simulation study of marine derived molecules for type 1 diabetes mellitus.
Mol Divers (2026). https://doi.org/10.1007/s11030-025-11453-7

Image Credits: AI Generated

DOI: https://doi.org/10.1007/s11030-025-11453-7

Keywords: Type 1 diabetes, marine-derived molecules, integrative gene mapping, RNA sequencing, molecular docking, ADMET profiling, molecular dynamics simulation.

The synthesis of fused pyrazolopyridopyrimidine derivatives is the fundamental cornerstone of the research, showcasing the intricate chemical processes and innovative methodologies employed to develop these novel compounds. The researchers meticulously designed and synthesized a series of these derivatives, utilizing advanced techniques that underscore the sophistication of modern organic synthesis. Each step of the synthesis was optimized to yield compounds with desirable pharmacological properties, culminating in a diverse library of candidates for subsequent biological evaluation. This aspect of the research emphasizes the marriage of theoretical chemistry and practical laboratory work, reflecting the meticulous attention to detail that is essential in drug development.

One of the prominent features of these compounds is their dual functionality as antioxidants and antimicrobial agents. Antioxidants play a crucial role in mitigating oxidative stress that can lead to various chronic diseases, including cancer, cardiovascular diseases, and neurodegenerative disorders. The fused pyrazolopyridopyrimidine derivatives exhibit promising free radical scavenging activity, paving the way for potential applications in therapeutic strategies aimed at enhancing cellular defense mechanisms. The dual action of these compounds is particularly noteworthy, as it addresses two pressing concerns in contemporary medicine—oxidative damage and microbial infections.

The research also delves into molecular docking studies, providing insights into the interaction between the synthesized compounds and their biological targets. By employing state-of-the-art computational techniques, the researchers modeled how these derivatives bind to specific receptors or enzymes involved in pathogenic processes. The results of the molecular docking studies were instrumental in identifying the most promising candidates for further evaluation, thereby streamlining the drug discovery process. This computational approach exemplifies the synergy between theoretical predictions and experimental validation, which is vital in expediting the development of new therapeutics.

ADMET studies constitute another significant aspect of the research. Evaluating the pharmacokinetic and toxicological properties of the compounds is essential to predict their behavior in biological systems. The researchers comprehensively analyzed the absorption, distribution, metabolism, excretion, and toxicity profiles of the synthesized derivatives. This thorough assessment serves as a critical gatekeeper, ensuring that only the most viable candidates proceed to clinical trials. Understanding these parameters allows scientists to anticipate potential challenges and optimize the structure of the compounds to enhance their therapeutic potential while minimizing side effects.

Biological evaluation of the fused pyrazolopyridopyrimidine derivatives followed the computational analyses to corroborate the in silico predictions. The researchers conducted various in vitro tests to assess the antimicrobial activity of the synthesized compounds against a spectrum of pathogenic microorganisms. The results were promising, showcasing robust antimicrobial activity against both Gram-positive and Gram-negative bacteria. This empirical evidence provides a solid foundation for the potential clinical utility of these compounds, positioning them as candidates for further investigation in the treatment of infectious diseases.

In addition to antimicrobial properties, the antioxidant capacity of the compounds was evaluated through a series of assays designed to measure their effectiveness in scavenging free radicals. The findings revealed that several derivatives exhibited significant antioxidant activity, highlighting their potential application in preventing oxidative damage. This aspect of the research is particularly relevant in the context of developing nutraceuticals or therapeutic agents aimed at managing oxidative stress-related conditions.

Furthermore, the safety profile of the synthesized derivatives is a critical consideration in medicinal chemistry. The researchers carefully assessed the toxicity of the compounds, utilizing various assays to establish their safety margins. By understanding the toxicological implications, the team was able to identify candidates that not only exhibit efficacy but also possess acceptable safety profiles, further bolstering their potential for therapeutic development.

Looking forward, the implications of this research extend beyond the academic sphere. The discovery of fused pyrazolopyridopyrimidine derivatives could inspire a new wave of drug development strategies aimed at combating both antimicrobial resistance and oxidative stress-related disorders. As the pharmaceutical industry grapples with the challenge of developing effective therapeutics, the findings from this research could pave the way for innovative drug design approaches that integrate both empirical and computational methodologies.

The collaborative efforts among the researchers are commendable, reflecting a multidisciplinary approach that enhances the overall rigor of the study. This research exemplifies how diverse expertise—from synthetic organic chemistry to computational biology—can converge to address pressing healthcare challenges. The team’s work not only contributes to the existing body of knowledge but also sets a precedent for future investigations aimed at uncovering novel therapeutic agents with dual functionality.

In summation, the synthesis, molecular docking, ADMET studies, and biological evaluation of fused pyrazolopyridopyrimidine derivatives represent a significant advancement in the search for novel antioxidants and antimicrobial agents. This research embodies the essence of cutting-edge medicinal chemistry, where traditional methods of drug discovery are augmented by modern computational techniques. The promising results underscore the potential of these derivatives in clinical applications, potentially offering new avenues for managing oxidative stress-related disorders and microbial infections in an increasingly challenging healthcare landscape.

As researchers continue to grapple with the evolving landscape of medicine, the study serves as a beacon of hope, illustrating the potential for novel compounds to emerge from innovative research. The exciting journey of these fused pyrazolopyridopyrimidine derivatives is just beginning, as further studies and clinical evaluations may ultimately determine their place within the arsenal of modern therapeutics.

Subject of Research: Synthesis and evaluation of fused pyrazolopyridopyrimidine derivatives as antioxidant and antimicrobial agents.

Article Title: Synthesis, molecular docking, ADMET studies and biological evaluation of fused pyrazolopyridopyrimidine derivatives as antioxidant and antimicrobial agents.

Article References:

Khalaf, H., El-Sayed, A., Sediek, A. et al. Synthesis, molecular docking, ADMET studies and biological evaluation of fused pyrazolopyridopyrimidine derivatives as antioxidant and antimicrobial agents.
Sci Rep (2025). https://doi.org/10.1038/s41598-025-30217-9

Image Credits: AI Generated

DOI: 10.1038/s41598-025-30217-9

Keywords: antioxidant agents, antimicrobial agents, fused pyrazolopyridopyrimidine derivatives, molecular docking, ADMET studies, drug discovery, medicinal chemistry.

This study investigates the potential of amygdalin, a natural compound found in almonds, peaches, and apples, as a therapeutic agent for HER2-positive breast cancer. HER2 (human epidermal growth factor receptor 2) is overexpressed in a significant percentage of aggressive breast cancer cases and is associated with poor prognosis. The researchers aimed to explore whether amygdalin could effectively bind to and stabilize the HER2 protein, which could suppress its cancer-promoting activity.

To do this, the study employed a variety of computational tools. Molecular docking was used to determine how strongly amygdalin could bind to HER2, and results showed favorable binding energies, especially when water molecules were included in the simulation. Molecular dynamics simulations over a 100-nanosecond period revealed that amygdalin binding induced structural changes in the HER2 protein, particularly reducing the flexibility of the dimerization arm and decreasing interdomain distances—features associated with an inactive HER2 conformation. The binding was shown to be energetically favorable, primarily driven by van der Waals forces, as revealed by MMPBSA energy calculations.

Finally, the study identified key amino acids within HER2 that contributed most to the binding interaction, and the presence of water was shown to enhance the stability and tightness of the binding. The authors conclude that while these computational results are promising and show that amygdalin could interfere with HER2 activity, further in vitro and clinical studies are needed to validate its effectiveness as a treatment option. Nonetheless, the findings offer a strong foundation for future drug development targeting HER2 in breast cancer.

Journal

LabMed Discovery

DOI

10.1016/j.lmd.2025.100070